TUBERCULOSIS TESTING IN PSORIASIS

FDA Labeling Now Aligns with the IPC and NPF Joint Position Statement

The International Psoriasis Council (IPC) and the National Psoriasis Foundation (NPF) published a joint position statement on routine latent tuberculosis testing. Labeling from the United States Food and Drug Administration (FDA) for two treatments used in psoriasis now aligns with that recommendation.

1

November 2025

IPC & NPF

The joint position statement publishes in *JAAD*: routine latent TB testing is **not required** before or during treatment with interleukin 17 or interleukin 23 inhibitors. **87.5%** of voting IPC Board Members, IPC Councilors, and NPF Medical Board members endorse it.

2

March 2026

FDA

FDA approves **icotrokinra** (Icotyde), a new oral psoriasis treatment, without a TB testing requirement. Its label leaves TB evaluation before treatment to **clinical judgment**, consistent with the IPC and NPF joint position statement.

3

October 2026

FDA

FDA revises the **risankizumab** prescribing information to the same wording: **consider evaluating** patients for TB before treatment **based on clinical judgment**, rather than directing that all patients be evaluated.

> For icotrokinra and risankizumab, FDA labeling no longer requires a TB test before starting treatment.

Blauvelt A, Strober BE, Eakin GS, et al. Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors. *J Am Acad Dermatol*. 2026;94(3):802-809. doi:10.1016/j.jaad.2025.11.033